ArticleAsian Pacific journal of cancer prevention : APJCP2017
Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma
Article in Asian Pacific journal of cancer prevention : APJCP, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Comparison of combined transarterial chemoembolization and ablations in patients with hepatocellular carcinoma: a systematic review and meta-analysis.Abdominal radiology (New York) · 2022Pooled it
- Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy?JHEP reports : innovation in hepatology · 2023Review
- Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023Review
- Indian College of Radiology and Imaging Guidelines on Interventions in Hepatocellular Carcinoma.The Indian journal of radiology & imaging · 2022Review
- Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?Journal of personalized medicine · 2022Review
- Radiofrequency ablation in the management of primary hepatic and biliary tumors.World journal of gastrointestinal oncology · 2022Review
- Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?World journal of gastrointestinal oncology · 2021Review
- The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma.Investigational new drugs · 2021Review
- Comparison of intrahepatic progression patterns of hepatocellular carcinoma and colorectal liver metastases following CT-guided high dose-rate brachytherapy.Therapeutic advances in medical oncology · 2021Article
- Multiple imaging modality-guided radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma in special locations.Diagnostic and interventional radiology (Ankara, Turkey) · 2020Article
- Ablative therapies for hepatic and biliary tumors: endohepatology coming of age.Translational gastroenterology and hepatology · 2020Review
- Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update.The oncologist · 2019Review
- Transcatheter arterial chemoembolization combined with simultaneous cone beam computed tomography-guided multipolar microwave ablation for massive hepatocellular carcinoma (≥10 cm): Safety and primary clinical results.Journal of interventional medicine · 2019Article
- The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma.Analytical cellular pathology (Amsterdam) · 2019Review
- Observational
- Nonviral Gene Therapy for Cancer: A Review.Diseases (Basel, Switzerland) · 2018Review
- A Winning New Combination? Toward Clinical Application in Oncology.Cancer control : journal of the Moffitt Cancer CenterReview
- 2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations.Journal of clinical and experimental hepatologyReview
- Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.Korean journal of radiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Local ablative therapy and trans arterial chemoembolization (TACE) are applied to ablate non resectable hepatocellular carcinoma (HCC). Combination of both techniques has proven to be more effective. We aimed to study combined ablation techniques and assess survival benefit comparing TACE with radiofrequency (RFA) versus TACE with microwave (MWA) techniques. Methods: We retrospectively studied 22 patients who were ablated using TACE-RFA and 45 with TACE-MWA. All were classified as Child A-B and lesions did not exceed 5 cm in diameter. TACE was followed within two weeks by either RFA or MWA. We recorded total and partial ablation rates and complication rates. Survival analysis was then performed. Results: TACE-MWA showed a higher tendency to provide complete response rates than TACE-RFA (P 0.06). This was particularly evident with lesions sized 3-5 cm (P 0.01). Rates of complications showed no significant difference between the groups. Overall median survival was 27 months. The overall actuarial probability of survival was 80.1% at 1 year, 55% at 2 years, and 36.3% at 3 years. The recurrence free survival at 1 year, 2years and 3 years for the TACE-RFA group was 70%, 42% and 14% respectively and for TACE-MWA group 81.2%, 65.1% and 65.1% without any significant difference (P 0.1). In relation to the size of focal lesions, no statistically significant difference in the survival rates was detected between the groups. Conclusion: TACE-MWA led to better response rates than TACE-RFA with tumors 3-5 cm, with no difference in survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.